+Follow
a0b7ff1
No personal profile
1
Follow
1
Followers
0
Topic
0
Badge
Posts
Hot
a0b7ff1
2022-01-17
good
Unilever to Weigh Raising Offer for Glaxo Consumer Unit
a0b7ff1
2022-01-10
👍
Sorry, the original content has been removed
Go to Tiger App to see more news
{"i18n":{"language":"en_US"},"userPageInfo":{"id":"4104738662177920","uuid":"4104738662177920","gmtCreate":1641639308484,"gmtModify":1704447498955,"name":"a0b7ff1","pinyin":"a0b7ff1","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":1,"fanSize":1,"headSize":1,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"init","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.10.10","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2024.04.06","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":3,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":1,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.01.14","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},"individualDisplayBadges":null,"crmLevel":3,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":9005789544,"gmtCreate":1642410152232,"gmtModify":1676533708646,"author":{"id":"4104738662177920","authorId":"4104738662177920","name":"a0b7ff1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104738662177920","idStr":"4104738662177920"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005789544","repostId":"2204238907","repostType":4,"repost":{"id":"2204238907","pubTimestamp":1642407154,"share":"https://ttm.financial/m/news/2204238907?lang=&edition=fundamental","pubTime":"2022-01-17 16:12","market":"us","language":"en","title":"Unilever to Weigh Raising Offer for Glaxo Consumer Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2204238907","media":"Bloomberg","summary":"Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, late","content":"<html><head></head><body><ul><li>Dove owner could sell some Glaxo assets to buyout firms</li><li>Pharma giant rejected $68 billion offer, latest of three bids</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6352a1547143383d73706a32a17038fb\" tg-width=\"1000\" tg-height=\"666\" width=\"100%\" height=\"auto\"/><span>Pfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/Bloomberg</span></p><p>Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, according to people familiar with the matter.</p><p>Some financial firms have discussed lending enough for a bid higher than 50 billion pounds ($68 billion) -- the latest of three offers Glaxo has rejected for a bundle of brands including Advil painkiller and Sensodyne toothpaste.</p><p>Unilever hasn’t made a final decision on using the firepower, said the people, who requested anonymity as they aren’t allowed to speak publicly. The owner of Ben & Jerry’s ice cream and Dove soap could eventually sell some non-core assets from the Glaxo portfolio to buyers including private equity firms, which could help fund an acquisition, the people said.</p><p>Glaxo over the weekend said it had rejected Unilever’s offers as too low after the U.K. consumer-products company confirmed its approach. The drugmaker said it’s sticking with plans to spin off the portfolio of brands.</p><p>Representatives for Unilever and Glaxo declined to comment.</p><p><b>Growth Prospects</b></p><p>Glaxo’s board is open to proposals but the latest bid late last year was not within a range the company would consider, the people said. The pharma giant talked up growth prospects for the unit, formed through a combination of its consumer labels with those of Pfizer Inc., which retains a minority stake.</p><p>A takeover would be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest globally in the past twelve months, and would come at a time when merger and acquisition activity is at an all-time high. It would also be Unilever’s biggest-ever deal, advancing Chief Executive Officer Alan Jope’s ambition to execute bigger and bolder acquisitions to reshape the company’s roster of labels.</p><p>Shortly after taking the helm in 2019, Jope signaled that the company was ready to progress past the tamer takeover strategy of former CEO Paul Polman, who had focused on incremental deals in fast-growing sectors such as male grooming and home care.</p><p>Jope’s three-year tenure has been mired in distractions and misfires that have held back the company’s stock. Fundsmith founder Terry Smith, one of Unilever’s top 15 shareholders, last week said the company had “lost the plot” with a focus on burnishing its sustainability credentials at the expense of financial performance.</p><p>Last year’s decision by Ben & Jerry’s to stop selling ice cream in Israeli settlements in the occupied Palestinian territories prompted several U.S. states to divest their stakes in Unilever. A planned sale of personal-care brands including Q-Tips and Tigi hair products was shelved in 2021 after failing to drum up interest. The company also had to settle for a sale of its tea operations to private-equity firm <a href=\"https://laohu8.com/S/CVC.AU\">CVC</a> Capital Partners after talking up prospects for an initial public offering.</p><p><b>Pandemic Effect</b></p><p>Some of Unilever’s woes have been outside of Jope’s control. In his first year as CEO, he warned that sales growth would fall short of expectations because of economic setbacks in Latin America. In 2020, the Covid-19 pandemic generated strong demand for the company’s soaps but dented revenue at its food-service division. Unilever now faces the risk of consumers defecting to discounted labels as it raises prices to counter inflation.</p><p>The shares are trading at a lower level than in 2017, when Polman rejected an unsolicited $143 billion offer from Kraft Heinz Co. Although Jope consolidated Unilever in the U.K., ending a cumbersome Anglo-Dutch legal structure in an effort to facilitate more transformational deals, his first public attempt at a high-profile takeover has so far come up short.</p><p>Glaxo is also under pressure from shareholders, including activist fund Elliott Investment Management LP, which has urged the drugmaker to consider a sale rather than a spinoff of the consumer brands. The pharma company has trailed rivals such as AstraZeneca Plc in developing new treatments.</p><p>Glaxo has said it expects sales at the business to increase by 4% to 6% in the medium term, which is faster than the growth rate at Unilever’s personal care division. With Jope’s interest now out in the open, other bidders could emerge.</p><p>Guiseppe Bivona, co-founder of Bluebell Partners, an activist hedge fund with a stake in Glaxo, called Unilever’s bid “encouraging.” “It’s a great asset and there should be broad interest in it,” he said.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unilever to Weigh Raising Offer for Glaxo Consumer Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnilever to Weigh Raising Offer for Glaxo Consumer Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 16:12 GMT+8 <a href=https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, latest of three bidsPfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UL":"联合利华(英国)"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204238907","content_text":"Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, latest of three bidsPfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/BloombergUnilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, according to people familiar with the matter.Some financial firms have discussed lending enough for a bid higher than 50 billion pounds ($68 billion) -- the latest of three offers Glaxo has rejected for a bundle of brands including Advil painkiller and Sensodyne toothpaste.Unilever hasn’t made a final decision on using the firepower, said the people, who requested anonymity as they aren’t allowed to speak publicly. The owner of Ben & Jerry’s ice cream and Dove soap could eventually sell some non-core assets from the Glaxo portfolio to buyers including private equity firms, which could help fund an acquisition, the people said.Glaxo over the weekend said it had rejected Unilever’s offers as too low after the U.K. consumer-products company confirmed its approach. The drugmaker said it’s sticking with plans to spin off the portfolio of brands.Representatives for Unilever and Glaxo declined to comment.Growth ProspectsGlaxo’s board is open to proposals but the latest bid late last year was not within a range the company would consider, the people said. The pharma giant talked up growth prospects for the unit, formed through a combination of its consumer labels with those of Pfizer Inc., which retains a minority stake.A takeover would be one of the largest globally in the past twelve months, and would come at a time when merger and acquisition activity is at an all-time high. It would also be Unilever’s biggest-ever deal, advancing Chief Executive Officer Alan Jope’s ambition to execute bigger and bolder acquisitions to reshape the company’s roster of labels.Shortly after taking the helm in 2019, Jope signaled that the company was ready to progress past the tamer takeover strategy of former CEO Paul Polman, who had focused on incremental deals in fast-growing sectors such as male grooming and home care.Jope’s three-year tenure has been mired in distractions and misfires that have held back the company’s stock. Fundsmith founder Terry Smith, one of Unilever’s top 15 shareholders, last week said the company had “lost the plot” with a focus on burnishing its sustainability credentials at the expense of financial performance.Last year’s decision by Ben & Jerry’s to stop selling ice cream in Israeli settlements in the occupied Palestinian territories prompted several U.S. states to divest their stakes in Unilever. A planned sale of personal-care brands including Q-Tips and Tigi hair products was shelved in 2021 after failing to drum up interest. The company also had to settle for a sale of its tea operations to private-equity firm CVC Capital Partners after talking up prospects for an initial public offering.Pandemic EffectSome of Unilever’s woes have been outside of Jope’s control. In his first year as CEO, he warned that sales growth would fall short of expectations because of economic setbacks in Latin America. In 2020, the Covid-19 pandemic generated strong demand for the company’s soaps but dented revenue at its food-service division. Unilever now faces the risk of consumers defecting to discounted labels as it raises prices to counter inflation.The shares are trading at a lower level than in 2017, when Polman rejected an unsolicited $143 billion offer from Kraft Heinz Co. Although Jope consolidated Unilever in the U.K., ending a cumbersome Anglo-Dutch legal structure in an effort to facilitate more transformational deals, his first public attempt at a high-profile takeover has so far come up short.Glaxo is also under pressure from shareholders, including activist fund Elliott Investment Management LP, which has urged the drugmaker to consider a sale rather than a spinoff of the consumer brands. The pharma company has trailed rivals such as AstraZeneca Plc in developing new treatments.Glaxo has said it expects sales at the business to increase by 4% to 6% in the medium term, which is faster than the growth rate at Unilever’s personal care division. With Jope’s interest now out in the open, other bidders could emerge.Guiseppe Bivona, co-founder of Bluebell Partners, an activist hedge fund with a stake in Glaxo, called Unilever’s bid “encouraging.” “It’s a great asset and there should be broad interest in it,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006262437,"gmtCreate":1641769718574,"gmtModify":1676533645413,"author":{"id":"4104738662177920","authorId":"4104738662177920","name":"a0b7ff1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"4104738662177920","idStr":"4104738662177920"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006262437","repostId":"2201214004","repostType":4,"isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":9005789544,"gmtCreate":1642410152232,"gmtModify":1676533708646,"author":{"id":"4104738662177920","authorId":"4104738662177920","name":"a0b7ff1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104738662177920","authorIdStr":"4104738662177920"},"themes":[],"htmlText":"good","listText":"good","text":"good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9005789544","repostId":"2204238907","repostType":4,"repost":{"id":"2204238907","pubTimestamp":1642407154,"share":"https://ttm.financial/m/news/2204238907?lang=&edition=fundamental","pubTime":"2022-01-17 16:12","market":"us","language":"en","title":"Unilever to Weigh Raising Offer for Glaxo Consumer Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2204238907","media":"Bloomberg","summary":"Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, late","content":"<html><head></head><body><ul><li>Dove owner could sell some Glaxo assets to buyout firms</li><li>Pharma giant rejected $68 billion offer, latest of three bids</li></ul><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/6352a1547143383d73706a32a17038fb\" tg-width=\"1000\" tg-height=\"666\" width=\"100%\" height=\"auto\"/><span>Pfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/Bloomberg</span></p><p>Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, according to people familiar with the matter.</p><p>Some financial firms have discussed lending enough for a bid higher than 50 billion pounds ($68 billion) -- the latest of three offers Glaxo has rejected for a bundle of brands including Advil painkiller and Sensodyne toothpaste.</p><p>Unilever hasn’t made a final decision on using the firepower, said the people, who requested anonymity as they aren’t allowed to speak publicly. The owner of Ben & Jerry’s ice cream and Dove soap could eventually sell some non-core assets from the Glaxo portfolio to buyers including private equity firms, which could help fund an acquisition, the people said.</p><p>Glaxo over the weekend said it had rejected Unilever’s offers as too low after the U.K. consumer-products company confirmed its approach. The drugmaker said it’s sticking with plans to spin off the portfolio of brands.</p><p>Representatives for Unilever and Glaxo declined to comment.</p><p><b>Growth Prospects</b></p><p>Glaxo’s board is open to proposals but the latest bid late last year was not within a range the company would consider, the people said. The pharma giant talked up growth prospects for the unit, formed through a combination of its consumer labels with those of Pfizer Inc., which retains a minority stake.</p><p>A takeover would be <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the largest globally in the past twelve months, and would come at a time when merger and acquisition activity is at an all-time high. It would also be Unilever’s biggest-ever deal, advancing Chief Executive Officer Alan Jope’s ambition to execute bigger and bolder acquisitions to reshape the company’s roster of labels.</p><p>Shortly after taking the helm in 2019, Jope signaled that the company was ready to progress past the tamer takeover strategy of former CEO Paul Polman, who had focused on incremental deals in fast-growing sectors such as male grooming and home care.</p><p>Jope’s three-year tenure has been mired in distractions and misfires that have held back the company’s stock. Fundsmith founder Terry Smith, one of Unilever’s top 15 shareholders, last week said the company had “lost the plot” with a focus on burnishing its sustainability credentials at the expense of financial performance.</p><p>Last year’s decision by Ben & Jerry’s to stop selling ice cream in Israeli settlements in the occupied Palestinian territories prompted several U.S. states to divest their stakes in Unilever. A planned sale of personal-care brands including Q-Tips and Tigi hair products was shelved in 2021 after failing to drum up interest. The company also had to settle for a sale of its tea operations to private-equity firm <a href=\"https://laohu8.com/S/CVC.AU\">CVC</a> Capital Partners after talking up prospects for an initial public offering.</p><p><b>Pandemic Effect</b></p><p>Some of Unilever’s woes have been outside of Jope’s control. In his first year as CEO, he warned that sales growth would fall short of expectations because of economic setbacks in Latin America. In 2020, the Covid-19 pandemic generated strong demand for the company’s soaps but dented revenue at its food-service division. Unilever now faces the risk of consumers defecting to discounted labels as it raises prices to counter inflation.</p><p>The shares are trading at a lower level than in 2017, when Polman rejected an unsolicited $143 billion offer from Kraft Heinz Co. Although Jope consolidated Unilever in the U.K., ending a cumbersome Anglo-Dutch legal structure in an effort to facilitate more transformational deals, his first public attempt at a high-profile takeover has so far come up short.</p><p>Glaxo is also under pressure from shareholders, including activist fund Elliott Investment Management LP, which has urged the drugmaker to consider a sale rather than a spinoff of the consumer brands. The pharma company has trailed rivals such as AstraZeneca Plc in developing new treatments.</p><p>Glaxo has said it expects sales at the business to increase by 4% to 6% in the medium term, which is faster than the growth rate at Unilever’s personal care division. With Jope’s interest now out in the open, other bidders could emerge.</p><p>Guiseppe Bivona, co-founder of Bluebell Partners, an activist hedge fund with a stake in Glaxo, called Unilever’s bid “encouraging.” “It’s a great asset and there should be broad interest in it,” he said.</p></body></html>","source":"lsy1584095487587","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Unilever to Weigh Raising Offer for Glaxo Consumer Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnilever to Weigh Raising Offer for Glaxo Consumer Unit\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-17 16:12 GMT+8 <a href=https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit><strong>Bloomberg</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, latest of three bidsPfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/...</p>\n\n<a href=\"https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"UL":"联合利华(英国)"},"source_url":"https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2204238907","content_text":"Dove owner could sell some Glaxo assets to buyout firmsPharma giant rejected $68 billion offer, latest of three bidsPfizer Products Ahead Of Earnings Release Photographer: Daniel Acker/BloombergUnilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc’s consumer products division, according to people familiar with the matter.Some financial firms have discussed lending enough for a bid higher than 50 billion pounds ($68 billion) -- the latest of three offers Glaxo has rejected for a bundle of brands including Advil painkiller and Sensodyne toothpaste.Unilever hasn’t made a final decision on using the firepower, said the people, who requested anonymity as they aren’t allowed to speak publicly. The owner of Ben & Jerry’s ice cream and Dove soap could eventually sell some non-core assets from the Glaxo portfolio to buyers including private equity firms, which could help fund an acquisition, the people said.Glaxo over the weekend said it had rejected Unilever’s offers as too low after the U.K. consumer-products company confirmed its approach. The drugmaker said it’s sticking with plans to spin off the portfolio of brands.Representatives for Unilever and Glaxo declined to comment.Growth ProspectsGlaxo’s board is open to proposals but the latest bid late last year was not within a range the company would consider, the people said. The pharma giant talked up growth prospects for the unit, formed through a combination of its consumer labels with those of Pfizer Inc., which retains a minority stake.A takeover would be one of the largest globally in the past twelve months, and would come at a time when merger and acquisition activity is at an all-time high. It would also be Unilever’s biggest-ever deal, advancing Chief Executive Officer Alan Jope’s ambition to execute bigger and bolder acquisitions to reshape the company’s roster of labels.Shortly after taking the helm in 2019, Jope signaled that the company was ready to progress past the tamer takeover strategy of former CEO Paul Polman, who had focused on incremental deals in fast-growing sectors such as male grooming and home care.Jope’s three-year tenure has been mired in distractions and misfires that have held back the company’s stock. Fundsmith founder Terry Smith, one of Unilever’s top 15 shareholders, last week said the company had “lost the plot” with a focus on burnishing its sustainability credentials at the expense of financial performance.Last year’s decision by Ben & Jerry’s to stop selling ice cream in Israeli settlements in the occupied Palestinian territories prompted several U.S. states to divest their stakes in Unilever. A planned sale of personal-care brands including Q-Tips and Tigi hair products was shelved in 2021 after failing to drum up interest. The company also had to settle for a sale of its tea operations to private-equity firm CVC Capital Partners after talking up prospects for an initial public offering.Pandemic EffectSome of Unilever’s woes have been outside of Jope’s control. In his first year as CEO, he warned that sales growth would fall short of expectations because of economic setbacks in Latin America. In 2020, the Covid-19 pandemic generated strong demand for the company’s soaps but dented revenue at its food-service division. Unilever now faces the risk of consumers defecting to discounted labels as it raises prices to counter inflation.The shares are trading at a lower level than in 2017, when Polman rejected an unsolicited $143 billion offer from Kraft Heinz Co. Although Jope consolidated Unilever in the U.K., ending a cumbersome Anglo-Dutch legal structure in an effort to facilitate more transformational deals, his first public attempt at a high-profile takeover has so far come up short.Glaxo is also under pressure from shareholders, including activist fund Elliott Investment Management LP, which has urged the drugmaker to consider a sale rather than a spinoff of the consumer brands. The pharma company has trailed rivals such as AstraZeneca Plc in developing new treatments.Glaxo has said it expects sales at the business to increase by 4% to 6% in the medium term, which is faster than the growth rate at Unilever’s personal care division. With Jope’s interest now out in the open, other bidders could emerge.Guiseppe Bivona, co-founder of Bluebell Partners, an activist hedge fund with a stake in Glaxo, called Unilever’s bid “encouraging.” “It’s a great asset and there should be broad interest in it,” he said.","news_type":1},"isVote":1,"tweetType":1,"viewCount":177,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":9006262437,"gmtCreate":1641769718574,"gmtModify":1676533645413,"author":{"id":"4104738662177920","authorId":"4104738662177920","name":"a0b7ff1","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":3,"crmLevelSwitch":0,"followedFlag":false,"idStr":"4104738662177920","authorIdStr":"4104738662177920"},"themes":[],"htmlText":"👍","listText":"👍","text":"👍","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/9006262437","repostId":"2201214004","repostType":4,"repost":{"id":"2201214004","pubTimestamp":1641604837,"share":"https://ttm.financial/m/news/2201214004?lang=&edition=fundamental","pubTime":"2022-01-08 09:20","market":"us","language":"en","title":"Want to Get Richer? 2 Top Growth Stocks to Buy and Hold","url":"https://stock-news.laohu8.com/highlight/detail?id=2201214004","media":"Motley Fool","summary":"As tempting as it may be, strategies built on market timing rarely work.","content":"<html><head></head><body><p>Warren Buffett once said that his favorite stock holding period is forever. Despite that advice, many investors tend to buy and sell quickly. In fact, the average holding period for shares on the <b>New York Stock Exchange</b> has trended downward over the last several decades, and it dropped below six months in June 2020.</p><p>So what? History tells us that whether the market is up or down in any given year is essentially a coin toss. In other words, if you're dipping in and out of stocks, you're not investing -- you're gambling. And there's nothing wrong with gambling, but if you're looking to build life-changing wealth, you're better off taking a buy-and-hold approach. A long-term mindset helps you avoid short-term volatility and it gives your investment theses time to play out.</p><p>Two stocks that could benefit an investor using a buy-and-hold approach are <b>Tesla</b> (NASDAQ:TSLA) and <b>Zscaler</b> (NASDAQ:ZS). Each has great potential to make you richer in the long run. Here's what you should know.</p><p class=\"t-img-caption\"><img src=\"https://static.tigerbbs.com/0b7755ea2b8be302b03c4454fb738f44\" tg-width=\"700\" tg-height=\"466\" referrerpolicy=\"no-referrer\"/><span>Image source: Getty Images.</span></p><h2>1. Tesla</h2><p>CEO Elon Musk has often said manufacturing efficiency would be Tesla's long-term advantage, and the company is making good on that notion. Its theoretical annual production capacity now exceeds 1 million electric vehicles (EVs), and despite headwinds created by chip shortages, Tesla delivered over 936,000 vehicles in 2021, up 87% from the prior year.</p><p>More importantly, as production capacity has scaled in both the U.S. and China, Tesla's cost per vehicle has fallen, dropping 55% between 2017 and the first quarter of 2021. That efficiency is due in part to Tesla's 2170 battery cell, a technology that Musk has called "the highest energy density cell in the world, and also the cheapest." To that end, Tesla pays an estimated $187 per kilowatt-hour (kWh) for its battery packs -- the most expensive part of an EV. That's 24% lower than the industry average and 10% lower than the next-closest competitor.</p><p>Additionally, through November 2021, Tesla held 13.7% market share in terms of EV sales, easily besting the second-place EV manufacturer <b>BYD</b>, which captured 9% market share. Collectively, the company's improving efficiency and its dominant position have translated into impressive financial results on both the top and bottom lines.</p><table><thead><tr><th><p>Metric</p></th><th><p>Q3 2019</p></th><th><p>Q3 2021</p></th><th><p>CAGR</p></th></tr></thead><tbody><tr><td width=\"156\"><p>Revenue (TTM)</p></td><td width=\"156\"><p>$24.4 million</p></td><td width=\"156\"><p>$46.9 billion</p></td><td width=\"156\"><p>39%</p></td></tr><tr><td width=\"156\"><p>Free cash flow (TTM)</p></td><td width=\"156\"><p>$873 million</p></td><td width=\"156\"><p>$2.6 billion</p></td><td width=\"156\"><p>71%</p></td></tr></tbody></table><p>Data source: YCharts. TTM = trailing 12 months. CAGR = compound annual growth rate.</p><p>Despite Tesla's past success, I think the company's best days are yet to come. Production of the Tesla Semi (a semi-tractor trailer) is slated to start in 2022, and the trucking industry is ripe for disruption. The company also plans to integrate its new 4680 battery cell into vehicles this year, a technology that should reinforce its current cost advantages. Specifically, management believes the 4680 battery cell will cut the cost per kWh by 56% and boost EV range by 54%.</p><p>Further down the road, Tesla aims to launch an autonomous ride-hailing service, a market that ARK Invest analysts value at $1.2 trillion by 2030. While Tesla's full self-driving software is still in the works, Musk has hinted that the company would have a fully autonomous $25,000 EV in late 2023 or 2024. But even if Tesla misses that target, the company still appears to have a big head start in the race to build a self-driving car. That's why I plan to hold this stock forever.</p><h2>2. Zscaler</h2><p>Zscaler specializes in cybersecurity. Its cloud platform, the Zero Trust Exchange, is spread across 150 data centers, creating a global network that is fast, safe, and reliable. This distributed architecture, known as a secure access service edge (SASE), allows clients to access corporate resources from any device or location, while also eliminating the IT burden of buying and managing on-site hardware. In short, Zscaler is the new corporate network.</p><p>Specifically, Zscaler Private Access (ZPA) safeguards internally managed resources, like software hosted in a private data center; and Zscaler Internet Access (ZIA) offers the same protection for externally managed resources, such as applications hosted in the public cloud. More recently, the company expanded its offering with Zscaler Digital <a href=\"https://laohu8.com/S/EXP.AU\">Experience</a> (ZDX), an infrastructure performance monitoring solution, and Zscaler Cloud Protection (ZCP), a suite of tools that allows clients to secure cloud workloads.</p><p>Collectively, those products fuel digital transformation, keeping corporate networks secure no matter whether the information is stored on-site or in the cloud, nor whether it's accessed by employees in the office or those working remotely. To that end, research firm <b>Gartner</b> believes 60% of enterprises will have plans in place to adopt SASE networks by 2025, up from just 10% in 2020.</p><p>More importantly, Gartner has recognized Zscaler as the industry leader for 10 consecutive years, and that advantage has been a powerful growth driver for this cybersecurity company.</p><table><thead><tr><th><p>Metric</p></th><th><p>Q1 2020</p></th><th><p>Q1 2022</p></th><th><p>CAGR</p></th></tr></thead><tbody><tr><td width=\"156\"><p>Revenue (TTM)</p></td><td width=\"156\"><p>$333.1 million</p></td><td width=\"156\"><p>$761.0 million</p></td><td width=\"156\"><p>51%</p></td></tr><tr><td width=\"156\"><p>Free cash flow (TTM)</p></td><td width=\"156\"><p>$33.5 million</p></td><td width=\"156\"><p>$184.9 million</p></td><td width=\"156\"><p>135%</p></td></tr></tbody></table><p>Data source: YCharts. TTM = trailing 12 months. CAGR = compound annual growth rate. Note: Q1 2022 ended Oct. 31, 2021.</p><p>Going forward, Zscaler has plenty of room to grow its business. The company currently serves 5,600 clients, comprising 26 million paid seats. But management puts the near-term opportunity at 335 million seats, which brings the company's addressable market to $72 billion. However, Zscaler could extend its services to smaller businesses (fewer than 2,000 employees), which would push its opportunity above 600 million seats.</p><p>More broadly, as the best-in-class network security solution, the company should see strong demand in the coming years as more enterprises seek to protect their sensitive data. That's why this growth stock looks like a smart buy for long-term investors.</p></body></html>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Want to Get Richer? 2 Top Growth Stocks to Buy and Hold</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWant to Get Richer? 2 Top Growth Stocks to Buy and Hold\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-01-08 09:20 GMT+8 <a href=https://www.fool.com/investing/2022/01/07/want-get-richer-top-growth-stocks-to-buy-and-hold/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Warren Buffett once said that his favorite stock holding period is forever. Despite that advice, many investors tend to buy and sell quickly. In fact, the average holding period for shares on the New ...</p>\n\n<a href=\"https://www.fool.com/investing/2022/01/07/want-get-richer-top-growth-stocks-to-buy-and-hold/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TSLA":"特斯拉","BK1511":"疑似财技股","BK1117":"系统软件","ZS":"Zscaler Inc."},"source_url":"https://www.fool.com/investing/2022/01/07/want-get-richer-top-growth-stocks-to-buy-and-hold/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2201214004","content_text":"Warren Buffett once said that his favorite stock holding period is forever. Despite that advice, many investors tend to buy and sell quickly. In fact, the average holding period for shares on the New York Stock Exchange has trended downward over the last several decades, and it dropped below six months in June 2020.So what? History tells us that whether the market is up or down in any given year is essentially a coin toss. In other words, if you're dipping in and out of stocks, you're not investing -- you're gambling. And there's nothing wrong with gambling, but if you're looking to build life-changing wealth, you're better off taking a buy-and-hold approach. A long-term mindset helps you avoid short-term volatility and it gives your investment theses time to play out.Two stocks that could benefit an investor using a buy-and-hold approach are Tesla (NASDAQ:TSLA) and Zscaler (NASDAQ:ZS). Each has great potential to make you richer in the long run. Here's what you should know.Image source: Getty Images.1. TeslaCEO Elon Musk has often said manufacturing efficiency would be Tesla's long-term advantage, and the company is making good on that notion. Its theoretical annual production capacity now exceeds 1 million electric vehicles (EVs), and despite headwinds created by chip shortages, Tesla delivered over 936,000 vehicles in 2021, up 87% from the prior year.More importantly, as production capacity has scaled in both the U.S. and China, Tesla's cost per vehicle has fallen, dropping 55% between 2017 and the first quarter of 2021. That efficiency is due in part to Tesla's 2170 battery cell, a technology that Musk has called \"the highest energy density cell in the world, and also the cheapest.\" To that end, Tesla pays an estimated $187 per kilowatt-hour (kWh) for its battery packs -- the most expensive part of an EV. That's 24% lower than the industry average and 10% lower than the next-closest competitor.Additionally, through November 2021, Tesla held 13.7% market share in terms of EV sales, easily besting the second-place EV manufacturer BYD, which captured 9% market share. Collectively, the company's improving efficiency and its dominant position have translated into impressive financial results on both the top and bottom lines.MetricQ3 2019Q3 2021CAGRRevenue (TTM)$24.4 million$46.9 billion39%Free cash flow (TTM)$873 million$2.6 billion71%Data source: YCharts. TTM = trailing 12 months. CAGR = compound annual growth rate.Despite Tesla's past success, I think the company's best days are yet to come. Production of the Tesla Semi (a semi-tractor trailer) is slated to start in 2022, and the trucking industry is ripe for disruption. The company also plans to integrate its new 4680 battery cell into vehicles this year, a technology that should reinforce its current cost advantages. Specifically, management believes the 4680 battery cell will cut the cost per kWh by 56% and boost EV range by 54%.Further down the road, Tesla aims to launch an autonomous ride-hailing service, a market that ARK Invest analysts value at $1.2 trillion by 2030. While Tesla's full self-driving software is still in the works, Musk has hinted that the company would have a fully autonomous $25,000 EV in late 2023 or 2024. But even if Tesla misses that target, the company still appears to have a big head start in the race to build a self-driving car. That's why I plan to hold this stock forever.2. ZscalerZscaler specializes in cybersecurity. Its cloud platform, the Zero Trust Exchange, is spread across 150 data centers, creating a global network that is fast, safe, and reliable. This distributed architecture, known as a secure access service edge (SASE), allows clients to access corporate resources from any device or location, while also eliminating the IT burden of buying and managing on-site hardware. In short, Zscaler is the new corporate network.Specifically, Zscaler Private Access (ZPA) safeguards internally managed resources, like software hosted in a private data center; and Zscaler Internet Access (ZIA) offers the same protection for externally managed resources, such as applications hosted in the public cloud. More recently, the company expanded its offering with Zscaler Digital Experience (ZDX), an infrastructure performance monitoring solution, and Zscaler Cloud Protection (ZCP), a suite of tools that allows clients to secure cloud workloads.Collectively, those products fuel digital transformation, keeping corporate networks secure no matter whether the information is stored on-site or in the cloud, nor whether it's accessed by employees in the office or those working remotely. To that end, research firm Gartner believes 60% of enterprises will have plans in place to adopt SASE networks by 2025, up from just 10% in 2020.More importantly, Gartner has recognized Zscaler as the industry leader for 10 consecutive years, and that advantage has been a powerful growth driver for this cybersecurity company.MetricQ1 2020Q1 2022CAGRRevenue (TTM)$333.1 million$761.0 million51%Free cash flow (TTM)$33.5 million$184.9 million135%Data source: YCharts. TTM = trailing 12 months. CAGR = compound annual growth rate. Note: Q1 2022 ended Oct. 31, 2021.Going forward, Zscaler has plenty of room to grow its business. The company currently serves 5,600 clients, comprising 26 million paid seats. But management puts the near-term opportunity at 335 million seats, which brings the company's addressable market to $72 billion. However, Zscaler could extend its services to smaller businesses (fewer than 2,000 employees), which would push its opportunity above 600 million seats.More broadly, as the best-in-class network security solution, the company should see strong demand in the coming years as more enterprises seek to protect their sensitive data. That's why this growth stock looks like a smart buy for long-term investors.","news_type":1},"isVote":1,"tweetType":1,"viewCount":258,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}
